All In Biotech

Drug Trial Radar · NCT00276172

Open-Label Natalizumab Safety Extension Study

An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803

Last checked: Nov 20, 2026Latest source record: Jun 22, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,615

Actual

Start

Dec 2003

Primary completion

Oct 2005

Study completion Jan 2006

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jan 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.

Conditions

  • Multiple Sclerosis

Interventions

  • NatalizumabDrug

    Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety endpoints under consideration will be the incidence of adverse events, changes in laboratory evaluations, vital signs, and physical examinations. The incidence of development of antibodies to natalizumab will also be assessed.Time frame: Month 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Performed at only C-1801, C-1802, and C-1803 sites globally. No general public enrollment. Biogen Idec is located in

    Cambridge, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.